These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 21412072)

  • 1. Expression of subtype-specific group 1 leiomyosarcoma markers in a wide variety of sarcomas by gene expression analysis and immunohistochemistry.
    Mills AM; Beck AH; Montgomery KD; Zhu SX; Espinosa I; Lee CH; Subramanian S; Fletcher CD; van de Rijn M; West RB
    Am J Surg Pathol; 2011 Apr; 35(4):583-9. PubMed ID: 21412072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of oxytocin receptor expression in distinguishing between uterine smooth muscle tumors and endometrial stromal sarcoma.
    Loddenkemper C; Mechsner S; Foss HD; Dallenbach FE; Anagnostopoulos I; Ebert AD; Stein H
    Am J Surg Pathol; 2003 Nov; 27(11):1458-62. PubMed ID: 14576480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling in leiomyosarcomas and undifferentiated pleomorphic sarcomas: SRC as a new diagnostic marker.
    Villacis RA; Silveira SM; Barros-Filho MC; Marchi FA; Domingues MA; Scapulatempo-Neto C; Aguiar S; Lopes A; Cunha IW; Rogatto SR
    PLoS One; 2014; 9(7):e102281. PubMed ID: 25028927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression profiling in soft tissue sarcomas with emphasis on synovial sarcoma, gastrointestinal stromal tumor, and leiomyosarcoma.
    West RB
    Adv Anat Pathol; 2010 Sep; 17(5):366-73. PubMed ID: 20733355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic signatures predict poor outcome in undifferentiated pleomorphic sarcomas and leiomyosarcomas.
    Silveira SM; Villacis RA; Marchi FA; Barros Filho Mde C; Drigo SA; Neto CS; Lopes A; da Cunha IW; Rogatto SR
    PLoS One; 2013; 8(6):e67643. PubMed ID: 23825676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases.
    Miettinen M; Furlong M; Sarlomo-Rikala M; Burke A; Sobin LH; Lasota J
    Am J Surg Pathol; 2001 Sep; 25(9):1121-33. PubMed ID: 11688571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas.
    Miettinen M; Sarlomo-Rikala M; Sobin LH; Lasota J
    Am J Surg Pathol; 2000 Feb; 24(2):211-22. PubMed ID: 10680889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of myocardin in the classification of mesenchymal tumors of the uterus.
    Liang J; Wu L; Xiao H; Li N; Wang H; Cheng C; Bai R; Zhao Y; Zheng H
    Int J Gynecol Pathol; 2010 Jan; 29(1):55-62. PubMed ID: 19952936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour.
    Edris B; Espinosa I; Mühlenberg T; Mikels A; Lee CH; Steigen SE; Zhu S; Montgomery KD; Lazar AJ; Lev D; Fletcher JA; Beck AH; West RB; Nusse R; van de Rijn M
    J Pathol; 2012 Jun; 227(2):223-33. PubMed ID: 22294416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases.
    Miettinen M; Kopczynski J; Makhlouf HR; Sarlomo-Rikala M; Gyorffy H; Burke A; Sobin LH; Lasota J
    Am J Surg Pathol; 2003 May; 27(5):625-41. PubMed ID: 12717247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma.
    Pazzaglia L; Novello C; Conti A; Pollino S; Picci P; Benassi MS
    Cell Oncol (Dordr); 2017 Feb; 40(1):77-88. PubMed ID: 27900663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma.
    Davidson B; Abeler VM; Hellesylt E; Holth A; Shih IeM; Skeie-Jensen T; Chen L; Yang Y; Wang TL
    Gynecol Oncol; 2013 Feb; 128(2):349-55. PubMed ID: 23178314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Low-grade leiomyosarcoma" and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas.
    Veras E; Zivanovic O; Jacks L; Chiappetta D; Hensley M; Soslow R
    Am J Surg Pathol; 2011 Nov; 35(11):1626-37. PubMed ID: 21921786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: different sides of a single coin?
    Carneiro A; Francis P; Bendahl PO; Fernebro J; Akerman M; Fletcher C; Rydholm A; Borg A; Nilbert M
    Lab Invest; 2009 Jun; 89(6):668-75. PubMed ID: 19290004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted RNA expression profiling identifies high-grade endometrial stromal sarcoma as a clinically relevant molecular subtype of uterine sarcoma.
    Momeni-Boroujeni A; Mohammad N; Wolber R; Yip S; Köbel M; Dickson BC; Hensley ML; Leitao MM; Antonescu CR; Benayed R; Ladanyi M; Lee CH; Chiang S
    Mod Pathol; 2021 May; 34(5):1008-1016. PubMed ID: 33077922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiating soft tissue leiomyosarcoma and undifferentiated pleomorphic sarcoma: A miRNA analysis.
    Guled M; Pazzaglia L; Borze I; Mosakhani N; Novello C; Benassi MS; Knuutila S
    Genes Chromosomes Cancer; 2014 Aug; 53(8):693-702. PubMed ID: 24771630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group.
    Croce S; Devouassoux-Shisheboran M; Pautier P; Ray-Coquard I; Treilleux I; Neuville A; Arnould L; Just PA; Belda MALF; Averous G; Leroux A; Mery E; Loussouarn D; Weinbreck N; Le Guellec S; Mishellany F; Morice P; Guyon F; Genestie C
    Gynecol Oncol; 2022 Nov; 167(2):373-389. PubMed ID: 36114030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleomorphic leiomyosarcoma: clinicopathologic and immunohistochemical study with special emphasis on its distinction from ordinary leiomyosarcoma and malignant fibrous histiocytoma.
    Oda Y; Miyajima K; Kawaguchi K; Tamiya S; Oshiro Y; Hachitanda Y; Oya M; Iwamoto Y; Tsuneyoshi M
    Am J Surg Pathol; 2001 Aug; 25(8):1030-8. PubMed ID: 11474287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of MCM2 With Ki67 and p16 Immunohistochemistry Can Distinguish Uterine Leiomyosarcomas.
    Keyhanian K; Lage JM; Chernetsova E; Sekhon H; Eslami Z; Islam S
    Int J Gynecol Pathol; 2020 Jul; 39(4):354-361. PubMed ID: 32515921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unsupervised analysis uncovers changes in histopathologic diagnosis in supervised genomic studies.
    Nykter M; Hunt KK; Pollock RE; El-Naggar AK; Taylor E; Shmulevich I; Yli-Harja O; Zhang W
    Technol Cancer Res Treat; 2006 Apr; 5(2):177-82. PubMed ID: 16551137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.